---
schema_version: "secwatch.filing_event.v1"
accession: "0001082554-23-000024"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T11:19:11.192587+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics Q2 2023: revenue $596.5M (+28%), net income $259.2M (+123%)

## Summary
- Total revenues $596.5M (+28% YoY), net income $259.2M (+123%), diluted EPS $5.24.
- Tyvaso (including DPI) sales $318.9M, up 59% YoY, driven by patient growth and inventory build.
- Orenitram sales $95.1M (+20%); Remodulin sales $127.2M (-4% YoY).
- CEO expects $4B annual revenue run rate by mid-decade with continued expansion.
- Share-based comp expense fell 79% to $13.8M due to stock price performance.

## SEC filing metadata
- accession: 0001082554-23-000024
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000108255423000024/0001082554-23-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000108255423000024/uthr-20230802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001082554-23-000024
- JSON: https://secwatch.observer/filing/0001082554-23-000024.json
- Plain text: https://secwatch.observer/filing/0001082554-23-000024.txt

## Key facts
- Earnings Releases
  UNITED THERAPEUTICS Corp reported the quarter ended June 30, 2023 results: revenue $596.5 million, net income $259.2 million, EPS $5.24 per diluted share. Guidance reaffirmed.
  - Period: the quarter ended June 30, 2023
  - Revenue: $596.5 million
  - Net income: $259.2 million
  - EPS: $5.24 per diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: Total revenues in the second quarter of 2023 grew 28% year-over-year to $596.5 million, compared to $466.9 million in the second quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1082554/000108255423000024/0001082554-23-000024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.